Page last updated: 2024-09-04

resiquimod and Melanoma

resiquimod has been researched along with Melanoma in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's4 (57.14)24.3611
2020's2 (28.57)2.80

Authors

AuthorsStudies
Geary, SM; Naguib, YW; Salem, AK; Tambunlertchai, S2
Allred, JB; Block, MS; Markovic, SN; Nevala, WK; Pang, YP; Strand, C1
Ambrosini, M; Bruijns, SC; de Gruijl, TD; Fehres, CM; Hooijberg, E; Kalay, H; Unger, WW; van Beelen, AJ; van Kooyk, Y1
Cooper, ZA; Dai, Z; Huang, XF; Hwu, P; Khong, H; Overwijk, WW; Singh, M; Vasilakos, JP; Wargo, JA1
Adams, S; Bhardwaj, N; Chiriboga, L; Cruz, CM; Darvishian, F; Escalon, J; Escano, C; Gnjatic, S; Goldberg, J; Hasan, F; Holman, RM; Jungbluth, A; Mandeli, J; Muren, C; Ott, PA; Pan, L; Pavlick, A; Rolnitzsky, L; Sabado, RL; Sharpe, D; Spadaccia, M; Vasilakos, JP; Vengco, I; Venhaus, R; Yepes, E1
Bong, AB; Drewniok, C; Eberle, J; Geilen, CC; Gollnick, H; Schön, M; Schön, MP; Wienrich, BG1

Trials

3 trial(s) available for resiquimod and Melanoma

ArticleYear
A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1.
    Melanoma research, 2019, Volume: 29, Issue:4

    Topics: Administration, Topical; Aged; Cancer Vaccines; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Cytokines; Female; Gene Products, gag; HLA-A2 Antigen; Humans; Imidazoles; Male; MART-1 Antigen; Melanoma; Middle Aged; Peptide Fragments; Pilot Projects; Skin Neoplasms

2019
Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.
    Cancer immunology research, 2015, Volume: 3, Issue:3

    Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antibodies, Neoplasm; Antibody Formation; Antigens, Neoplasm; Cancer Vaccines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Humans; Imidazoles; Immunity, Cellular; Male; Mannitol; Melanoma; Membrane Proteins; Middle Aged; Oleic Acids; Peptide Fragments; Vaccination

2015
Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod.
    The Journal of investigative dermatology, 2004, Volume: 122, Issue:5

    Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Biopsy; Cell Line, Tumor; fas Receptor; Humans; Imidazoles; Imiquimod; Melanocytes; Melanoma; Membrane Glycoproteins; Proto-Oncogene Proteins c-bcl-2; Receptors, Tumor Necrosis Factor; Skin Neoplasms; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha

2004

Other Studies

4 other study(ies) available for resiquimod and Melanoma

ArticleYear
Investigating silver nanoparticles and resiquimod as a local melanoma treatment.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2023, Volume: 183

    Topics: Animals; CD8-Positive T-Lymphocytes; Melanoma; Metal Nanoparticles; Mice; Silver

2023
Anti-melanoma Effects of Resiquimod (RSQ) In Vitro and in Combination with Immune Checkpoint Blockade In Vivo.
    The AAPS journal, 2023, 06-02, Volume: 25, Issue:4

    Topics: Animals; Immune Checkpoint Inhibitors; Immunotherapy; Melanoma; Mice; Skin Neoplasms; Tumor Microenvironment

2023
Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming.
    European journal of immunology, 2014, Volume: 44, Issue:8

    Topics: Administration, Topical; Aminoquinolines; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cross-Priming; Cytokines; Dendritic Cells; Humans; Imidazoles; Imiquimod; Injections, Intradermal; Ligands; MART-1 Antigen; Melanoma; Skin; Toll-Like Receptor 7

2014
Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.
    Journal of immunology (Baltimore, Md. : 1950), 2014, Nov-01, Volume: 193, Issue:9

    Topics: Adaptive Immunity; Animals; Antibodies, Monoclonal; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Chemokine CCL2; CTLA-4 Antigen; Cytotoxicity, Immunologic; Imidazoles; Immunity, Innate; Injections, Intralesional; Leukocytes; Lymphocytes, Tumor-Infiltrating; Melanoma; Melanoma, Experimental; Mice; Nitric Oxide; Phenotype; Toll-Like Receptor 7; Toll-Like Receptor 8; Tumor Burden

2014